itraconazole ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
systemic antifungal agents, miconazole derivatives 1513 84625-61-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • itraconazole
  • canditral
  • itrizole
  • oriconazole
  • traconal
  • triasporin
  • R-51211
A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.
  • Molecular weight: 705.64
  • Formula: C35H38Cl2N8O4
  • CLOGP: 6.84
  • LIPINSKI: 3
  • HAC: 12
  • HDO: 0
  • TPSA: 100.79
  • ALOGS: -4.86
  • ROTB: 11

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O
0.20 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.03 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 14.17 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 55 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 7.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 25 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 11, 1992 FDA JANSSEN PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 321.82 15.24 299 10816 199322 50394687
Aspergillus infection 130.52 15.24 51 11064 6770 50587239
Bronchopulmonary aspergillosis 115.04 15.24 48 11067 7544 50586465
Febrile neutropenia 113.72 15.24 123 10992 97544 50496465
Pseudohyponatraemia 101.56 15.24 16 11099 31 50593978
Symmetrical drug-related intertriginous and flexural exanthema 96.20 15.24 21 11094 341 50593668
Drug resistance 73.53 15.24 48 11067 18941 50575068
Myopathy 64.26 15.24 34 11081 9105 50584904
Rhabdomyolysis 63.50 15.24 59 11056 38968 50555041
Hepatic function abnormal 58.24 15.24 52 11063 32629 50561380
Cytomegalovirus test positive 55.35 15.24 21 11094 2571 50591438
Pathogen resistance 51.18 15.24 25 11090 5664 50588345
Neutrophil count decreased 48.36 15.24 55 11060 45971 50548038
Pain 47.39 15.24 35 11080 578868 50015141
Acute graft versus host disease 46.76 15.24 21 11094 3937 50590072
Adrenal suppression 46.29 15.24 14 11101 858 50593151
Cytomegalovirus infection 45.39 15.24 35 11080 17927 50576082
Skin candida 44.43 15.24 15 11100 1311 50592698
Labelled drug-drug interaction medication error 44.30 15.24 28 11087 10449 50583560
Contraindicated product prescribed 43.18 15.24 13 11102 784 50593225
Trichosporon infection 42.11 15.24 10 11105 240 50593769
Sepsis 41.82 15.24 91 11024 132834 50461175
Adrenal insufficiency 40.98 15.24 30 11085 14213 50579796
Liver disorder 39.99 15.24 45 11070 37177 50556832
Hypokalaemia 39.53 15.24 70 11045 87922 50506087
Neutropenic sepsis 38.91 15.24 29 11086 14118 50579891
Septic shock 38.87 15.24 55 11060 57120 50536889
Fungal endocarditis 37.86 15.24 9 11106 217 50593792
Pseudoaldosteronism 37.06 15.24 7 11108 52 50593957
Scedosporium infection 36.68 15.24 10 11105 422 50593587
Neutropenia 36.39 15.24 92 11023 147873 50446136
Platelet count decreased 36.39 15.24 73 11042 100653 50493356
Corneal perforation 35.59 15.24 10 11105 472 50593537
Cardiotoxicity 35.38 15.24 21 11094 7006 50587003
Abdominal discomfort 34.37 15.24 5 11110 231636 50362373
Histoplasmosis disseminated 33.28 15.24 12 11103 1274 50592735
Transplant rejection 31.70 15.24 22 11093 9587 50584422
Cytomegalovirus viraemia 31.64 15.24 17 11098 4692 50589317
Pneumonia 31.57 15.24 165 10950 378236 50215773
Ileus paralytic 31.13 15.24 16 11099 4034 50589975
Oedema 30.45 15.24 55 11060 70126 50523883
Pneumonia fungal 30.16 15.24 16 11099 4304 50589705
Immune reconstitution inflammatory syndrome associated tuberculosis 29.66 15.24 8 11107 324 50593685
Acute graft versus host disease in skin 29.37 15.24 14 11101 3004 50591005
Pleural effusion 29.37 15.24 59 11056 81395 50512614
Swelling 28.30 15.24 5 11110 200867 50393142
Thrombocytopenia 27.92 15.24 76 11039 127597 50466412
Eye infection fungal 27.57 15.24 6 11109 96 50593913
Fatigue 27.56 15.24 73 11042 707528 49886481
Pyrexia 26.51 15.24 158 10957 380045 50213964
Disseminated intravascular coagulation 26.12 15.24 25 11090 17110 50576899
Infective pulmonary exacerbation of cystic fibrosis 25.84 15.24 18 11097 7891 50586118
Pancreatitis haemorrhagic 25.66 15.24 7 11108 296 50593713
Blood lactate dehydrogenase increased 25.13 15.24 26 11089 19536 50574473
White blood cell count decreased 25.04 15.24 69 11046 116653 50477356
Acute myeloid leukaemia 24.91 15.24 23 11092 15051 50578958
Graft versus host disease 24.87 15.24 16 11099 6150 50587859
Cholestatic liver injury 24.76 15.24 11 11104 2010 50591999
Rheumatoid arthritis 24.61 15.24 7 11108 202543 50391466
Moraxella infection 24.54 15.24 7 11108 349 50593660
Duplicate therapy error 24.01 15.24 5 11110 64 50593945
Multiple organ dysfunction syndrome 23.83 15.24 41 11074 50296 50543713
Cardiac failure 23.82 15.24 52 11063 75988 50518021
Drug level increased 23.66 15.24 25 11090 19243 50574766
Liver function test abnormal 23.51 15.24 38 11077 44301 50549708
Electrocardiogram QT prolonged 22.93 15.24 41 11074 51845 50542164
Candida infection 22.84 15.24 27 11088 23496 50570513
Respiratory failure 22.71 15.24 57 11058 91124 50502885
Klebsiella infection 22.63 15.24 16 11099 7178 50586831
Product dispensing issue 22.58 15.24 5 11110 87 50593922
Varicella zoster virus infection 22.57 15.24 11 11104 2478 50591531
Duodenal atresia 22.27 15.24 3 11112 0 50594009
Fungal infection 22.11 15.24 30 11085 29935 50564074
Implant site hypersensitivity 21.92 15.24 4 11111 24 50593985
Cross sensitivity reaction 21.85 15.24 10 11105 1959 50592050
Cardiac valve vegetation 21.81 15.24 6 11109 262 50593747
Erythema multiforme 21.48 15.24 17 11098 9033 50584976
Cystic fibrosis 21.11 15.24 11 11104 2853 50591156
Joint swelling 21.08 15.24 14 11101 245272 50348737
Pseudomonas infection 20.87 15.24 17 11098 9413 50584596
Drug hypersensitivity 20.68 15.24 15 11100 250995 50343014
Exposure during pregnancy 20.68 15.24 66 11049 120949 50473060
Fall 20.63 15.24 26 11089 334906 50259103
Drug-induced liver injury 20.54 15.24 28 11087 28067 50565942
Immunosuppressant drug level increased 20.35 15.24 11 11104 3071 50590938
Blood prolactin increased 20.29 15.24 11 11104 3088 50590921
Thrombotic microangiopathy 19.77 15.24 16 11099 8775 50585234
Hypercholesterolaemia 19.61 15.24 18 11097 11685 50582324
Blast cell count increased 19.49 15.24 6 11109 390 50593619
Lung transplant rejection 19.24 15.24 7 11108 762 50593247
Myositis 19.06 15.24 15 11100 7905 50586104
Disseminated varicella zoster vaccine virus infection 19.01 15.24 4 11111 54 50593955
Systemic lupus erythematosus 18.74 15.24 4 11111 140618 50453391
Hypogammaglobulinaemia 18.68 15.24 13 11102 5686 50588323
Cystitis haemorrhagic 18.47 15.24 11 11104 3691 50590318
Galactorrhoea 18.41 15.24 11 11104 3712 50590297
Product dose omission issue 17.91 15.24 9 11106 183829 50410180
Conjunctival haemorrhage 17.72 15.24 10 11105 3034 50590975
Hypertension 17.48 15.24 92 11023 211111 50382898
Culture stool positive 16.83 15.24 5 11110 288 50593721
Systemic mycosis 16.83 15.24 7 11108 1090 50592919
Oedema peripheral 16.82 15.24 74 11041 157887 50436122
Cushing's syndrome 16.59 15.24 6 11109 642 50593367
Arthropathy 16.52 15.24 7 11108 157899 50436110
Staphylococcal sepsis 16.24 15.24 13 11102 7023 50586986
Drug-disease interaction 16.05 15.24 5 11110 338 50593671
Candida pneumonia 15.99 15.24 4 11111 120 50593889
Therapeutic product effect decreased 15.97 15.24 5 11110 136045 50457964
Engraft failure 15.95 15.24 5 11110 345 50593664
Pneumonia cytomegaloviral 15.89 15.24 8 11107 1933 50592076
Alanine aminotransferase increased 15.83 15.24 49 11066 88310 50505699
Arthralgia 15.73 15.24 47 11068 438655 50155354
Skin oedema 15.50 15.24 6 11109 775 50593234
Infusion related reaction 15.50 15.24 9 11106 169548 50424461
Toxic epidermal necrolysis 15.46 15.24 21 11094 20971 50573038
Septic embolus 15.25 15.24 6 11109 809 50593200

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 184.29 14.96 325 13165 197060 29363977
Aspergillus infection 114.22 14.96 67 13423 10514 29550523
Bronchopulmonary aspergillosis 94.89 14.96 63 13427 12281 29548756
Febrile neutropenia 93.10 14.96 176 13314 112064 29448973
Pathogen resistance 91.85 14.96 53 13437 8063 29552974
Drug resistance 89.47 14.96 76 13414 21464 29539573
Cardiotoxicity 78.90 14.96 40 13450 4704 29556333
Fungal infection 73.20 14.96 56 13434 13629 29547408
Neutrophil count decreased 58.56 14.96 85 13405 43482 29517555
Hepatic function abnormal 57.80 14.96 80 13410 39179 29521858
Parathyroid gland enlargement 57.14 14.96 13 13477 117 29560920
Upper respiratory fungal infection 56.00 14.96 13 13477 129 29560908
Platelet count decreased 54.40 14.96 136 13354 104536 29456501
Phaeohyphomycosis 52.55 14.96 18 13472 782 29560255
Cytomegalovirus test positive 51.54 14.96 27 13463 3396 29557641
Forced expiratory volume 48.86 14.96 11 13479 94 29560943
Bronchopulmonary aspergillosis allergic 47.51 14.96 15 13475 503 29560534
Drug level increased 43.33 14.96 48 13442 18739 29542298
Cytomegalovirus infection 43.01 14.96 53 13437 23162 29537875
Drug ineffective 42.70 14.96 297 13193 362873 29198164
Histoplasmosis disseminated 39.30 14.96 16 13474 1128 29559909
Acute myeloid leukaemia recurrent 38.60 14.96 18 13472 1762 29559275
Mycobacterial infection 37.88 14.96 18 13472 1838 29559199
Renal impairment 37.41 14.96 101 13389 81232 29479805
Fluorosis 37.06 14.96 8 13482 55 29560982
Hypokalaemia 36.98 14.96 75 13415 50128 29510909
Disseminated intravascular coagulation 34.43 14.96 44 13446 19936 29541101
Obliterative bronchiolitis 32.92 14.96 14 13476 1102 29559935
White blood cell count decreased 31.99 14.96 97 13393 83265 29477772
Fatigue 31.16 14.96 61 13429 316760 29244277
Blood lactate dehydrogenase increased 31.07 14.96 41 13449 19168 29541869
Bronchiectasis 31.00 14.96 25 13465 6560 29554477
Philadelphia positive acute lymphocytic leukaemia 30.93 14.96 6 13484 22 29561015
Adrenal insufficiency 30.23 14.96 31 13459 11083 29549954
Granulomatous rosacea 30.22 14.96 8 13482 141 29560896
Myopathy 29.78 14.96 30 13460 10503 29550534
Bronchial disorder 29.14 14.96 13 13477 1148 29559889
Apparent mineralocorticoid excess 28.65 14.96 6 13484 35 29561002
Lung transplant rejection 27.90 14.96 11 13479 713 29560324
Death 27.84 14.96 73 13417 342011 29219026
Tendon disorder 27.54 14.96 16 13474 2462 29558575
Pseudomonas infection 27.24 14.96 29 13461 10823 29550214
Acute graft versus host disease 27.18 14.96 22 13468 5802 29555235
Acute graft versus host disease in skin 26.96 14.96 20 13470 4644 29556393
Symmetrical drug-related intertriginous and flexural exanthema 26.81 14.96 8 13482 221 29560816
Neutrophil Pelger-Huet anomaly present 26.19 14.96 8 13482 240 29560797
Pyrexia 25.74 14.96 221 13269 287401 29273636
Haemoptysis 25.34 14.96 48 13442 30502 29530535
Pneumonia fungal 25.24 14.96 21 13469 5756 29555281
Pneumonia 25.09 14.96 239 13251 319933 29241104
Graft versus host disease 24.65 14.96 26 13464 9602 29551435
Neutropenia 24.64 14.96 122 13368 131589 29429448
Secretion discharge 24.21 14.96 18 13472 4192 29556845
Cystitis haemorrhagic 24.11 14.96 19 13471 4823 29556214
Obstructive airways disorder 23.44 14.96 27 13463 10989 29550048
Myositis 23.23 14.96 26 13464 10257 29550780
Hyperventilation 22.99 14.96 14 13476 2348 29558689
Polyomavirus-associated nephropathy 22.92 14.96 16 13474 3380 29557657
Capillaritis 22.87 14.96 6 13484 102 29560935
Ileus paralytic 22.84 14.96 19 13471 5204 29555833
Sinus congestion 22.75 14.96 18 13472 4594 29556443
Cerebrovascular accident 22.43 14.96 4 13486 76907 29484130
Liver disorder 22.28 14.96 43 13447 27706 29533331
Fall 22.20 14.96 29 13461 177149 29383888
Trichosporon infection 22.15 14.96 9 13481 631 29560406
Drug abuse 21.54 14.96 5 13485 79878 29481159
Ubiquinone decreased 21.23 14.96 4 13486 12 29561025
Cardiovascular insufficiency 21.01 14.96 11 13479 1382 29559655
Pseudoaldosteronism 20.83 14.96 5 13485 58 29560979
Post transplant lymphoproliferative disorder 20.01 14.96 18 13472 5475 29555562
Cytomegalovirus viraemia 19.72 14.96 19 13471 6301 29554736
Contraindicated product prescribed 19.67 14.96 7 13483 341 29560696
Pain 19.54 14.96 30 13460 171402 29389635
Neuropathy peripheral 18.76 14.96 73 13417 70954 29490083
Transplant rejection 18.64 14.96 22 13468 9190 29551847
Acute graft versus host disease in liver 18.58 14.96 10 13480 1328 29559709
Back pain 18.41 14.96 12 13478 102272 29458765
Oedema 18.31 14.96 50 13440 40433 29520604
Acute graft versus host disease in intestine 18.10 14.96 12 13478 2329 29558708
Lymphadenopathy 17.93 14.96 37 13453 25012 29536025
Condition aggravated 17.85 14.96 121 13369 146174 29414863
Product dose omission issue 17.76 14.96 11 13479 96372 29464665
Neuropsychiatric symptoms 17.28 14.96 7 13483 487 29560550
Epstein-Barr virus infection 17.14 14.96 18 13472 6611 29554426
Respiratory disorder 17.05 14.96 29 13461 16954 29544083
Pulmonary haemorrhage 16.90 14.96 21 13469 9249 29551788
Adrenal suppression 16.78 14.96 7 13483 525 29560512
Aspergilloma 16.73 14.96 6 13484 299 29560738
Folliculitis 16.67 14.96 14 13476 3886 29557151
Multiple-drug resistance 16.67 14.96 14 13476 3886 29557151
Aspartate aminotransferase increased 16.27 14.96 62 13428 59663 29501374
Sepsis 16.22 14.96 116 13374 142566 29418471
Drug level changed 16.14 14.96 6 13484 331 29560706
Alanine aminotransferase increased 15.66 14.96 69 13421 70875 29490162
Pseudomonal sepsis 15.64 14.96 12 13478 2930 29558107
Feeling abnormal 15.51 14.96 3 13487 54442 29506595
Cushingoid 15.32 14.96 11 13479 2427 29558610

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 437.88 13.74 570 21044 361513 64115605
Aspergillus infection 210.60 13.74 105 21509 16274 64460844
Bronchopulmonary aspergillosis 187.08 13.74 102 21512 18983 64458135
Drug resistance 159.21 13.74 115 21499 34987 64442131
Pathogen resistance 157.09 13.74 79 21535 12464 64464654
Febrile neutropenia 147.76 13.74 242 21372 187415 64289703
Symmetrical drug-related intertriginous and flexural exanthema 114.40 13.74 29 21585 592 64476526
Cardiotoxicity 112.15 13.74 59 21555 10215 64466903
Ileus paralytic 96.64 13.74 50 21564 8365 64468753
Myopathy 91.93 13.74 63 21551 17617 64459501
Neutrophil count decreased 81.13 13.74 114 21500 77082 64400036
Hepatic function abnormal 79.83 13.74 103 21511 64210 64412908
Pseudohyponatraemia 77.71 13.74 16 21598 121 64476997
Fungal infection 69.94 13.74 71 21543 34180 64442938
Phaeohyphomycosis 68.86 13.74 22 21592 1052 64476066
Platelet count decreased 68.10 13.74 164 21450 167547 64309571
Drug level increased 66.41 13.74 69 21545 34127 64442991
Cytomegalovirus test positive 66.16 13.74 33 21581 5111 64472007
Completed suicide 62.66 13.74 3 21611 224411 64252707
Cytomegalovirus infection 61.61 13.74 69 21545 37130 64439988
Pain 60.44 13.74 58 21556 553453 63923665
Hypokalaemia 60.37 13.74 129 21485 121774 64355344
Contraindicated product prescribed 59.09 13.74 20 21594 1147 64475971
Fatigue 56.71 13.74 103 21511 748627 63728491
Adrenal suppression 56.58 13.74 20 21594 1307 64475811
Trichosporon infection 56.07 13.74 18 21596 874 64476244
Pseudoaldosteronism 54.93 13.74 12 21602 124 64476994
Pneumonia fungal 54.28 13.74 35 21579 8842 64468276
Adrenal insufficiency 54.10 13.74 51 21563 22436 64454682
Histoplasmosis disseminated 52.04 13.74 21 21593 1977 64475141
Pneumonia 51.60 13.74 342 21272 559234 63917884
Granulomatous rosacea 49.80 13.74 12 21602 197 64476921
Rhabdomyolysis 48.82 13.74 100 21514 91626 64385492
Parathyroid gland enlargement 48.62 13.74 11 21603 135 64476983
Forced expiratory volume 47.96 13.74 10 21604 81 64477037
Transplant rejection 46.79 13.74 42 21572 17359 64459759
Lung transplant rejection 45.33 13.74 17 21597 1315 64475803
Acute graft versus host disease in skin 44.33 13.74 28 21586 6827 64470291
Blood lactate dehydrogenase increased 44.23 13.74 55 21559 33023 64444095
White blood cell count decreased 43.61 13.74 134 21480 157703 64319415
Myositis 42.99 13.74 39 21575 16338 64460780
Graft versus host disease 42.50 13.74 36 21578 13777 64463341
Liver disorder 42.13 13.74 69 21545 53282 64423836
Bronchopulmonary aspergillosis allergic 42.08 13.74 17 21597 1605 64475513
Pseudomonas infection 41.95 13.74 40 21574 17843 64459275
Skin candida 41.28 13.74 17 21597 1686 64475432
Pleural effusion 41.25 13.74 114 21500 126445 64350673
Oedema 40.65 13.74 93 21521 91842 64385276
Upper respiratory fungal infection 40.50 13.74 11 21603 296 64476822
Labelled drug-drug interaction medication error 40.13 13.74 43 21571 22019 64455099
Fall 39.54 13.74 49 21565 416777 64060341
Drug ineffective 39.48 13.74 442 21172 839805 63637313
Acute graft versus host disease 39.43 13.74 29 21585 9055 64468063
Acute myeloid leukaemia recurrent 39.20 13.74 19 21595 2765 64474353
Cytomegalovirus viraemia 39.15 13.74 31 21583 10797 64466321
Cystitis haemorrhagic 38.19 13.74 27 21587 7929 64469189
Rheumatoid arthritis 38.12 13.74 5 21609 164289 64312829
Fluorosis 36.59 13.74 8 21606 83 64477035
Drug hypersensitivity 36.52 13.74 17 21597 237798 64239320
Neuropathy peripheral 36.47 13.74 104 21510 117421 64359697
Neutropenia 35.02 13.74 166 21448 239458 64237660
Renal impairment 34.87 13.74 112 21502 134905 64342213
Product dose omission issue 34.74 13.74 11 21603 194736 64282382
Disseminated intravascular coagulation 34.29 13.74 48 21566 32300 64444818
Obliterative bronchiolitis 33.99 13.74 17 21597 2648 64474470
Pyrexia 33.91 13.74 310 21304 558334 63918784
Bronchiectasis 33.88 13.74 32 21582 14108 64463010
Mycobacterial infection 32.15 13.74 17 21597 2971 64474147
Scedosporium infection 32.04 13.74 13 21601 1241 64475877
Sepsis 31.81 13.74 157 21457 230184 64246934
Fungal endocarditis 30.98 13.74 10 21604 494 64476624
Apparent mineralocorticoid excess 29.93 13.74 6 21608 39 64477079
Cardiac failure 29.92 13.74 105 21509 132268 64344850
Septic shock 29.55 13.74 90 21524 105347 64371771
Joint swelling 29.25 13.74 18 21596 215364 64261754
Swelling 28.66 13.74 9 21605 160209 64316909
Abdominal discomfort 28.03 13.74 13 21601 182309 64294809
Corneal perforation 27.99 13.74 10 21604 674 64476444
Cushingoid 27.98 13.74 22 21592 7581 64469537
Philadelphia positive acute lymphocytic leukaemia 27.73 13.74 6 21608 59 64477059
Post transplant lymphoproliferative disorder 27.58 13.74 24 21590 9520 64467598
Aspergilloma 27.17 13.74 9 21605 483 64476635
Infective pulmonary exacerbation of cystic fibrosis 26.94 13.74 26 21588 11770 64465348
Injection site pain 26.80 13.74 3 21611 111405 64365713
Respiratory failure 26.77 13.74 116 21498 161067 64316051
Dizziness 25.96 13.74 67 21547 430096 64047022
Neutrophil Pelger-Huet anomaly present 25.83 13.74 8 21606 345 64476773
Musculoskeletal stiffness 25.76 13.74 5 21609 123201 64353917
Candida infection 25.29 13.74 41 21573 31378 64445740
Back pain 25.20 13.74 28 21586 250143 64226975
Arthralgia 25.09 13.74 71 21543 442189 64034929
Peripheral swelling 25.07 13.74 20 21594 209133 64267985
Infusion related reaction 24.86 13.74 12 21602 164455 64312663
Headache 24.52 13.74 93 21521 529374 63947744
Polyomavirus-associated nephropathy 24.42 13.74 17 21597 4871 64472247
Acute graft versus host disease in intestine 23.98 13.74 15 21599 3594 64473524
Liver function test abnormal 23.97 13.74 58 21556 59343 64417775
Eye infection fungal 23.91 13.74 8 21606 443 64476675
Sputum increased 23.88 13.74 15 21599 3620 64473498
Pneumonia cytomegaloviral 23.83 13.74 16 21598 4323 64472795
Candida pneumonia 23.60 13.74 8 21606 461 64476657
Multiple organ dysfunction syndrome 23.39 13.74 81 21533 101332 64375786
Haemoptysis 23.21 13.74 51 21563 48997 64428121
Arthropathy 23.10 13.74 6 21608 120961 64356157
Alanine aminotransferase increased 23.03 13.74 100 21514 138931 64338187
Fusarium infection 22.98 13.74 11 21603 1558 64475560
Product use in unapproved indication 22.69 13.74 118 21496 176500 64300618
Toxicity to various agents 22.40 13.74 56 21558 363457 64113661
Cross sensitivity reaction 22.39 13.74 14 21600 3353 64473765
Acute myeloid leukaemia 22.32 13.74 36 21578 27427 64449691
Blast cell count increased 21.93 13.74 10 21604 1269 64475849
Pneumonia bacterial 21.72 13.74 26 21588 15009 64462109
Pulmonary alveolar haemorrhage 21.37 13.74 21 21593 9717 64467401
Acute lymphocytic leukaemia 21.36 13.74 15 21599 4356 64472762
Varicella zoster virus infection 20.55 13.74 14 21600 3874 64473244
Immune reconstitution inflammatory syndrome 20.41 13.74 23 21591 12447 64464671
Implant site hypersensitivity 20.23 13.74 4 21610 24 64477094
Product dispensing issue 20.21 13.74 5 21609 92 64477026
Bronchial disorder 19.88 13.74 11 21603 2104 64475014
Capillaritis 19.86 13.74 6 21608 238 64476880
Therapeutic product effect decreased 19.72 13.74 7 21607 115344 64361774
Immune reconstitution inflammatory syndrome associated tuberculosis 19.70 13.74 8 21606 765 64476353
Ubiquinone decreased 19.58 13.74 4 21610 29 64477089
Cerebrovascular accident 19.37 13.74 11 21603 137572 64339546
Blood creatine phosphokinase increased 19.31 13.74 53 21561 58505 64418613
Acute graft versus host disease in liver 19.30 13.74 10 21604 1677 64475441
Pseudomonal sepsis 19.11 13.74 15 21599 5157 64471961
Disseminated varicella zoster vaccine virus infection 19.03 13.74 5 21609 118 64477000
Moraxella infection 18.92 13.74 7 21607 521 64476597
Systemic mycosis 18.91 13.74 11 21603 2312 64474806
Chronic granulomatous disease 18.81 13.74 4 21610 36 64477082
Electrocardiogram QT prolonged 18.79 13.74 64 21550 79384 64397734
Burkholderia cepacia complex infection 18.78 13.74 6 21608 287 64476831
Oedema peripheral 18.34 13.74 127 21487 210190 64266928
Mucormycosis 18.33 13.74 17 21597 7324 64469794
Pancreatitis haemorrhagic 18.23 13.74 7 21607 578 64476540
Staphylococcal sepsis 18.13 13.74 22 21592 12877 64464241
Cushing's syndrome 18.10 13.74 8 21606 943 64476175
Multiple-drug resistance 18.08 13.74 16 21598 6486 64470632
Lung infiltration 17.83 13.74 28 21586 20861 64456257
Cardiovascular insufficiency 17.67 13.74 11 21603 2613 64474505
Histoplasmosis 17.60 13.74 10 21604 2012 64475106
Hyperhidrosis 17.57 13.74 10 21604 124910 64352208
Aspartate aminotransferase increased 17.48 13.74 83 21531 119705 64357413
Differentiation syndrome 17.45 13.74 10 21604 2044 64475074
Corneal epithelium defect 17.15 13.74 7 21607 678 64476440
Hypogammaglobulinaemia 16.87 13.74 19 21595 10280 64466838
Thrombocytopenia 16.58 13.74 130 21484 223671 64253447
Chronic graft versus host disease 16.58 13.74 15 21599 6261 64470857
Systemic lupus erythematosus 16.54 13.74 3 21611 77609 64399509
Tumour lysis syndrome 16.51 13.74 26 21588 19414 64457704
Tendon disorder 16.46 13.74 15 21599 6317 64470801
Duplicate therapy error 16.44 13.74 5 21609 203 64476915
Disease recurrence 16.33 13.74 34 21580 31476 64445642
BK virus infection 16.29 13.74 16 21598 7396 64469722
Jaundice 16.09 13.74 44 21570 48468 64428650
Depression 15.86 13.74 23 21591 183268 64293850
Cytomegalovirus infection reactivation 15.68 13.74 14 21600 5742 64471376
Lower respiratory tract infection fungal 15.66 13.74 7 21607 848 64476270
Drug level changed 15.65 13.74 6 21608 493 64476625
Drug-induced liver injury 15.59 13.74 43 21571 47600 64429518
Bone marrow failure 15.41 13.74 43 21571 47909 64429209
Cystic fibrosis 14.99 13.74 11 21603 3423 64473695
Neuropsychiatric symptoms 14.84 13.74 7 21607 959 64476159
Pain in extremity 14.81 13.74 52 21562 303033 64174085
Death 14.74 13.74 98 21516 482607 63994511
Immunosuppressant drug level increased 14.72 13.74 15 21599 7244 64469874
Alternaria infection 14.69 13.74 6 21608 582 64476536
Nausea 14.63 13.74 181 21433 785619 63691499
Engraft failure 14.47 13.74 6 21608 605 64476513
Obstructive airways disorder 14.41 13.74 27 21587 23158 64453960
Growth retardation 14.34 13.74 8 21606 1553 64475565
Iron overload 14.34 13.74 8 21606 1554 64475564
Cholestatic liver injury 14.31 13.74 11 21603 3668 64473450
Pseudohypoaldosteronism 14.21 13.74 3 21611 26 64477092
Haemophagocytic lymphohistiocytosis 14.20 13.74 23 21591 17586 64459532
Hypersensitivity 13.93 13.74 28 21586 196424 64280694
Condition aggravated 13.92 13.74 188 21426 372238 64104880
Blood immunoglobulin E increased 13.88 13.74 11 21603 3833 64473285
Overdose 13.83 13.74 20 21594 159546 64317572
Cortisol decreased 13.81 13.74 8 21606 1669 64475449

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J02AC02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
Triazole and tetrazole derivatives
FDA CS M0002083 Azoles
FDA EPC N0000175487 Azole Antifungal
CHEBI has role CHEBI:50183 P450 inhibitors
CHEBI has role CHEBI:77748 steroid-transporting ATPase inhibitor
CHEBI has role CHEBI:140921 Hedgehog pathway inhibitors
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000190113 Breast Cancer Resistance Protein Inhibitors
MeSH PA D058888 14-alpha Demethylase Inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
MeSH PA D065692 Cytochrome P-450 CYP3A Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006727 Hormone Antagonists
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D065088 Steroid Synthesis Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Invasive pulmonary aspergillosis indication 3214003
Histoplasmosis indication 12962009 DOID:1731
Candidiasis of the esophagus indication 20639004 DOID:13146
Fusarium infection indication 64250002
Aspergillosis indication 65553006 DOID:13564
Blastomycosis indication 69996000 DOID:12663
Disseminated candidiasis indication 70572005
Onychomycosis of fingernails indication 403058003
Onychomycosis of toenails indication 403059006
Candidemia indication 432261003
Fungal Infection due to Scedosporium Apiospermum indication
Fungal Infection due to Fusarium Solani indication
Oropharyngeal Candidiasis indication
Coccidioidomycosis off-label use 60826002 DOID:13450
Chromoblastomycosis off-label use 187079000
Infection due to Penicillium marneffei off-label use 372936000
Onychomycosis due to dermatophyte off-label use 402134005
Heart valve disorder contraindication 368009 DOID:4079
Hypocalcemia contraindication 5291005
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Hearing loss contraindication 15188001
Torsades de pointes contraindication 31722008
Hypokalemia contraindication 43339004
Ventricular arrhythmia contraindication 44103008
Achlorhydria contraindication 47481007
Chronic heart failure contraindication 48447003
Hypochlorhydria contraindication 55961006
Heart failure contraindication 84114007 DOID:6000
Cardiomyopathy contraindication 85898001 DOID:0050700
Kidney disease contraindication 90708001 DOID:557
Prolonged QT interval contraindication 111975006
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Edema contraindication 267038008
Pregnancy, function contraindication 289908002
Peripheral nerve disease contraindication 302226006
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Poor metabolizer due to cytochrome p450 CYP2C19 variant contraindication 424500005
Congenital long QT syndrome contraindication 442917000




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Cats Dermatophytosis caused by Microsporum canis Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Itrafungol Virbac AH Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.12 Basic
pKa2 5.0 Basic
pKa3 3.04 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
200MG ONMEL SEBELA IRELAND LTD N022484 April 29, 2010 DISCN TABLET ORAL 8486456 Oct. 3, 2028 ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS
65MG TOLSURA MAYNE PHARMA INTL N208901 Dec. 11, 2018 RX CAPSULE ORAL 10463740 June 21, 2033 TREATMENT OF FUNGAL INFECTIONS, INCLUDING BLASTOMYCOSIS, HISTOPLASMOSIS, AND ASPERGILLOSIS
65MG TOLSURA MAYNE PHARMA INTL N208901 Dec. 11, 2018 RX CAPSULE ORAL 9713642 June 21, 2033 TREATMENT OF FUNGAL INFECTIONS, INCLUDING BLASTOMYCOSIS, HISTOPLASMOSIS, AND ASPERGILLOSIS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cytochrome P450 3A4 Enzyme IC50 6.05 DRUG MATRIX
Vasopressin V2 receptor GPCR IC50 6.10 CHEMBL
Tyrosine-protein kinase Fyn Kinase IC50 5.41 DRUG MATRIX
Lanosterol 14-alpha demethylase Enzyme IC50 5.44 CHEMBL
C-C chemokine receptor type 4 GPCR IC50 6.70 CHEMBL
C-X-C chemokine receptor type 1 GPCR IC50 7 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 6.30 CHEMBL
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase Enzyme IC50 5.33 CHEMBL
Lanosterol 14-alpha demethylase Enzyme INHIBITOR MIC 9.25 WOMBAT-PK CHEMBL
Cruzipain Enzyme IC50 5.52 CHEMBL
14-alpha sterol demethylase Cyp51A Enzyme Kd 6 CHEMBL
14-alpha sterol demethylase Enzyme Kd 7.51 CHEMBL

External reference:

IDSource
4020560 VUID
N0000148264 NUI
D00350 KEGG_DRUG
4020560 VANDF
C0064113 UMLSCUI
CHEBI:6076 CHEBI
1YN PDB_CHEM_ID
CHEMBL22587 ChEMBL_ID
CHEMBL64391 ChEMBL_ID
CHEMBL1711 ChEMBL_ID
D017964 MESH_DESCRIPTOR_UI
DB01167 DRUGBANK_ID
11426 IUPHAR_LIGAND_ID
5387 INN_ID
304NUG5GF4 UNII
3793 PUBCHEM_CID
28031 RXNORM
4940 MMSL
64593 MMSL
d00102 MMSL
003915 NDDF
387532006 SNOMEDCT_US
96038009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 0378-5100 CAPSULE 100 mg ORAL ANDA 24 sections
itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 10147-0150 SOLUTION 10 mg ORAL NDA 28 sections
itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 10147-1700 CAPSULE 100 mg ORAL NDA 30 sections
Itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-463 CAPSULE 100 mg ORAL ANDA 14 sections
Itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-463 CAPSULE 100 mg ORAL ANDA 14 sections
Itraconazole Human Prescription Drug Label 1 16714-743 CAPSULE, COATED PELLETS 100 mg ORAL ANDA 21 sections
Itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 16729-271 CAPSULE 100 mg ORAL ANDA 25 sections
Itraconazole Human Prescription Drug Label 1 31722-006 SOLUTION 10 mg ORAL ANDA 15 sections
ITRACONAZOLE Human Prescription Drug Label 1 46708-204 CAPSULE 100 mg ORAL ANDA 22 sections
Itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 49884-239 CAPSULE 100 mg ORAL ANDA 22 sections
Itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 50268-450 CAPSULE 100 mg ORAL ANDA 13 sections
SPORANOX HUMAN PRESCRIPTION DRUG LABEL 1 50458-290 CAPSULE 100 mg ORAL NDA 29 sections
SPORANOX HUMAN PRESCRIPTION DRUG LABEL 1 50458-295 SOLUTION 10 mg ORAL NDA 28 sections
Tolsura HUMAN PRESCRIPTION DRUG LABEL 1 51862-462 CAPSULE, GELATIN COATED 65 mg ORAL NDA 31 sections
Tolsura HUMAN PRESCRIPTION DRUG LABEL 1 51862-462 CAPSULE, GELATIN COATED 65 mg ORAL NDA 31 sections
itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 59746-282 CAPSULE 100 mg ORAL ANDA 17 sections
Itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 60687-299 CAPSULE 100 mg ORAL ANDA 14 sections
ITRACONAZOLE Human Prescription Drug Label 1 62332-204 CAPSULE 100 mg ORAL ANDA 22 sections
ITRACONAZOLE Human Prescription Drug Label 1 62332-204 CAPSULE 100 mg ORAL ANDA 22 sections
Itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 63629-8168 CAPSULE, COATED PELLETS 100 mg ORAL ANDA 21 sections
Itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 65162-087 SOLUTION 10 mg ORAL ANDA 22 sections
Itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 65162-630 CAPSULE 100 mg ORAL ANDA 13 sections
Itraconazole Human Prescription Drug Label 1 67877-454 CAPSULE, COATED PELLETS 100 mg ORAL ANDA 21 sections
itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 68151-2718 CAPSULE 100 mg ORAL NDA 27 sections
itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 68382-697 CAPSULE 100 mg ORAL ANDA 14 sections
Itraconazole Oral HUMAN PRESCRIPTION DRUG LABEL 1 69339-159 SOLUTION 10 mg ORAL ANDA 26 sections
Itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 70518-2872 CAPSULE, COATED PELLETS 100 mg ORAL ANDA 21 sections
ITRACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 70518-3264 CAPSULE 100 mg ORAL ANDA 22 sections
itraconazole HUMAN PRESCRIPTION DRUG LABEL 1 70771-1208 CAPSULE 100 mg ORAL ANDA 1 sections
CICLOPIROX 3% / ITRACONAZOLE 5% / UREA 20% HUMAN PRESCRIPTION DRUG LABEL 3 72934-2044 CREAM 5 g TOPICAL unapproved drug other 4 sections